Institutional Owners0

Institutional Stock Ownership and Shareholders

AUROBINDO PHARMA LTD. (BSE:524804) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
AUROBINDO PHARMA LTD. (BSE:524804) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Prev Value
Current Value

Related News Stories

Amidst Strong Quarterly Growth, Novartis Receives FDA Complete Response Letter for Canakinumab

9h biospace
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for canakinumab as a potential treatment for cardiovascular risk reduction.

HDFC Bank, LT Infotech among top 5 momentum plays for 5-15% returns

2018-10-16 moneycontrol
The equity market opened on a cautious note but managed to close in the positive after buying in last hour of trade on October 15. It was a volatile session of trade for Nifty but it managed to close at 10,512 up by 0.38 percent. (1-0)

Outbound activity drives Merger and Acquisition’s robust growth in Q3 of 2018

2018-10-15 financialexpress
Merger and acquisition (M&A) deal values recorded a 5.3-times increase year-on-year (y-o-y) in the third quarter of calendar year 2018 (Q32018) driven by outbound activity, according to a dealtracker report by Grant Thornton. The report stated that M&A deal values stood at $11.506 billion in Q32018 compared with $2.147 billion in the same period last year.

UPDATE 1-EU places China's Zhejiang Huahai under increased supervision

2018-10-15 reuters
(Reuters) - European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.

India Inc#39;s Jan-Sep MA deal tally touch $76 bn: Report

2018-10-15 moneycontrol
Corporate India announced merger and acquisitions (M&As) worth $11.5 billion in the third quarter of this year, following which the January-September deal tally stood at $76.03 billion, says a report.